Adefovir dipivoxil is effective for the treatment of cirrhotic patients with lamivudine failure

Liver International

Volumn 29, Issue 3, 2009, Pages 420-426

  Zoulim, Fabien ^a,b,c   Parvaz, Parviz ^a,b,d   Marcellin, Patrick ^e   Zarski, Jean Pierre ^f   Beaugrand, Michel ^g   Benhamou, Yves ^h   Bailly, François ^a,b,c   Maynard, Marianne ^a,b,c   Trepo, Christian ^a,b,c   Trylesinski, Aldo ⁱ   Monchecourt, Françoise ⁱ   Boyer, N ^e   Esnault, V ^e   Calmus, Y ^j   Houssin, D ^j   Rosenberg, A ^j   Dhumeaux, D ^k   Hezode, C ^k   Bouvier Alias, M ^k   Pol, S ^l   Nalpas, A ^l   Poynard, T ^h   Thibault, V ^h   Poupon, R ^m   Serfaty, L ^m   Gozlan, Y ^m   Pialoux, G ⁿ   Grange, J D ⁿ   Ahloulay, M ⁿ   Ganne, N ^g   Baazia, Y ^g   Fournet, J ^f   Plages, A ^f   Bourliere M ^o   Lecomte, L ^o   Deydier, R ^o   Cadranel, J F ^p   Dumouchel, P ^p   Couzigou, P ^q   Foucher, J ^q   Castera, L ^q   Grange, I ^d   Bronowicki, J P ^r   Tricon, L ^r   Venard, V ^r   Lerebours, E ^s   Goria, O ^s   Chefson, C ^s   Baladaud, P ^t   Bernard, P H ^t   Jouvencel, A C ^t   Barange, K ^u   Vinel, J P ^u   Jaafar, M ^u   Kazatchkine, M ^v   Aouba, A ^v   Tisserand, P ^v   more..

^a INSERM   (France)

^b UNIVERSITÉ LYON 1   (France)

^c HÔTEL DIEU   (France)

^d HOSPICES CIVILS DE LYON   (France)

^e BEAUJON HOSPITAL   (France)

^f GRENOBLE UNIVERSITY HOSPITAL   (France)

^g HÔPITAL JEAN VERDIER   (France)

^h PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

ⁱ Gilead Sciences   (France)

^j Institut Cochin   (France)

^k HENRI MONDOR HOSPITAL   (France)

^l HÔPITAL NECKER ENFANTS MALADES   (France)

^m HÔPITAL SAINT ANTOINE   (France)

ⁿ HÔPITAL TENON   (France)

^o HÔPITAL SAINT JOSEPH   (France)

^p CENTRE HOSPITALIER LAENNEC   (France)

^q HAUT LÉVÊQUE HOSPITAL   (France)

^r CHU NANCY BRABOIS   (France)

^s HÔPITAL CHARLES NICOLLE   (France)

^t HÔPITAL SAINT ANDRÉ   (France)

^u CHU PURPAN   (France)

^v HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

more..

Author keywords

Adefovir dipivoxil; Chronic hepatitis B; Cirrhosis; Elderly; Lamivudine failure

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; FAMCICLOVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ABSENCE OF SIDE EFFECTS; ADD ON THERAPY; ADULT; AGED; ALCOHOL CONSUMPTION; ANTIVIRAL RESISTANCE; ARTICLE; BIOCHEMISTRY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ELDERLY CARE; FEMALE; FOLLOW UP; GENE MUTATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; SEROCONVERSION; TREATMENT DURATION; TREATMENT OUTCOME; VIROLOGY;

ADENINE; ADULT; AGED; ALANINE TRANSAMINASE; COHORT STUDIES; DRUG RESISTANCE; FEMALE; GENOTYPE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; RETROSPECTIVE STUDIES;

EID: 59849090681     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2008.01867.x     Document Type: Article

References (27)

1. Lok AS. Chronic hepatitis B. N Engl J Med 2002; 346: 1682-3.
2. De Jongh FE, Janssen HL, De Man RA, Hop WC, Schalm SW, Van Blankenstein M. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992; 103: 1630-5.
3. Janssen HL, Van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: A randomised trial. Lancet 2005; 365: 123-9.
4. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682-95.
5. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-17.
6. Marcellin P, Samuel D, Areias J, et al. Pretransplantation interferon treatment and recurrence of hepatitis B virus infection after liver transplantation for hepatitis B-related end-stage liver disease. Hepatology 1994; 19: 6-12.
7. Chang TT, Gish RG, De Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 1001-10.
8. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348: 800-7.
9. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339: 61-8.
10. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 1011-20.
11. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808-16.
12. Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357: 2576-88.
13. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-31.
14. Villeneuve JP, Durantel D, Durantel S, et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol 2003; 39: 1085-9.
15. Lai CL, Dienstag J, Schiff E, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36: 687-96.
16. Nafa S, Ahmed S, Tavan D, et al. Early detection of viral resistance by determination of Hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic Hepatitis B. Hepatology 2000; 32: 1078-88.
17. Zoulim F, Poynard T, Degos F, et al. A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine. J Viral Hepat 2006; 13: 278-88.
18. Perrillo R, Hann HW, Mutimer D, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004; 126: 81-90.
19. Peters MG, Hann HWH, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004; 126: 91-101.
20. Schiff ER, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003; 38: 1419-27.
21. Benhamou Y, Fleury H, Trimoulet P, et al. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. Hepatology 2006; 43: 548-55.
22. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 1743-51.
23. Sherman M, Yurdaydin C, Sollano J, et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006; 130: 2039-49.
24. Zoulim F, Perrillo R. Hepatitis B: Reflections on the current approach to antiviral therapy. J Hepatol 2008; 48(Suppl. 1): S2-19.
25. Fung SK, Chae HB, Fontana RJ, et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006; 44: 283-90.
26. Lampertico P, Vigano M, Manenti E. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 2005; 42: 1414-9.
27. Lampertico P, Vigano M, Manenti E, Iavarone M, Sablon E, Colombo M. Low resistance to adefovir combined with lamivudine: A 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007; 133: 1445-51.